BFRI — Biofrontera Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1858685 ·
Last close
$0.59
Market Cap
$8.81M
52W High
$1.66
52W Low
$0.54
ADV30
209,601
Next earnings
—
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 12,003,000 9,593,000 -524,000 -604,000 24,064,000 4,659,000 18,108,000
Mar 2026 10,084,000 7,968,000 -3,928,000 -4,752,000 24,787,000 6,317,000 18,717,000
Dec 2025 17,100,000 14,091,000 4,559,000 5,640,000 28,564,000 6,392,000 18,084,000
Sep 2025 6,988,000 4,943,000 -6,278,000 -6,649,000 15,415,000 3,417,000 17,996,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,927,000
Investing CF
$2,997,000
Financing CF
$10,850,000
CapEx
$-9,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.60
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-133,301,000
Inventory
$1,330,000
Receivables
$5,625,000
ST Investments
$8,000
EBIT TTM
$-5,512,000
Pretax Income TTM
$-6,336,000
Interest Exp TTM
$472,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$46,175,000
EBITDA
$-5,968,000
Free Cash Flow
$-7,597,750
Enterprise Value
$13,235,137
Total Cash
$4,667,000
Total Debt
$7,504,000
Shares Out
14,852,359
Trailing EPS
$-0.43
Book Value
$0.90
ROE
-988.4%
ROA
-17.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 41,705,000 -11,348,000 -10,536,000 28,564,000 18,084,000 10,480,000 -13,361,000
Dec 2024 37,321,000 -17,210,000 -17,759,000 22,101,000 17,668,000 4,433,000 -10,270,000
Dec 2023 34,071,000 -22,577,000 -20,131,000 27,932,000 23,139,000 4,793,000 -24,895,000
Dec 2022 28,674,000 -22,381,000 -640,000 50,884,000 27,006,000 23,878,000 -16,199,000

TTM Snapshot

Revenues TTM
$46,174,000
NetIncome TTM
$-6,365,000
OpCashFlow TTM
—
Assets (Latest)
$24,064,000
Forward EPS
$0.43

Peers — same industry

TickerNameMarket CapLastDaily %
LEXX Lexaria Bioscience Corp. $8.81M $4.18 —
PHIO Phio Pharmaceuticals Corp. $8.57M $0.72 —
DARE Dare Bioscience, Inc. $8.44M $0.43 —
CALC CalciMedica, Inc. $8.41M $1.22 —
CLRB Cellectar Biosciences, Inc. $9.24M $0.92 —

News headlines (Yahoo Finance, 1h cache)

Biofrontera: 3 Key Takeaways for Long-Term Investors
2026-11-17 19:55 · Yahoo
Biofrontera Inc. Q3 2026 Earnings Call Summary
2026-11-13 21:50 · Yahoo
Biofrontera (BFRI) Q3 2026 Earnings Call Transcript
2026-11-13 21:13 · Yahoo
Biofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth
2026-11-13 13:02 · Yahoo
Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026
2026-11-06 23:08 · Yahoo
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
2026-10-08 13:22 · Yahoo
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
2026-09-14 13:26 · Yahoo
Biofrontera (BFRI) Q2 2026 Earnings Call Transcript
2026-08-20 15:58 · Yahoo
Biofrontera Inc (BFRI) (Q2 2026) Earnings Call Highlights: Strong Ameluz Growth Drives Revenue ...
2026-08-13 23:03 · Yahoo
Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates
2026-08-13 14:10 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.